Indian boxing star Mary Kom opened up on the heartache she faced returning to competition after having children as she captured her first Commonwealth Games title on Saturday at the age of 35.
Mother-of-three Kom, the subject of a Bollywood film in 2014, won a unanimous points decision over Northern Ireland's Kristina O'Hara in their light-flyweight final on Australia's Gold Coast.
It is Kom's first Commonwealth medal of any colour and burnishes a heaving trophy cabinet that already includes an Olympic bronze from London 2012 and five amateur world championship titles.
The trail-blazer, known in India as "Magnificent Mary", celebrated with a victory parade on her coach's shoulders and she had tears in her eyes afterwards.
Kom, devastated not to gain a wildcard for the 2016 Rio Olympics, gave mixed signals about whether she would now target the Tokyo 2020 Games and a first Olympic gold.
"That is difficult to say, but I will try," said Kom, who is already older than most of her opponents.
Part of the problem is that at the Olympics there is no light-flyweight category, meaning Kom would have to step up to flyweight, which would mean fighting bigger and stronger opponents.
"If I am still super-fit in another year I will try," she added of another tilt at a maiden Olympic gold.
"If I am not enough fit, maybe I will retire."
Kom, who went from a poor village life to sports stardom and celebrity, has three sons -- twin boys aged 10 and another of five.
They are not boxing fans.
"It's very hard," said Kom, reflecting on returning to the boxing ring after the birth of her youngest child.
"My husband and parents are very supportive, but if I wasn't strong that would not be possible.
"I'm still strong from here and here," said Kom, pointing to her heart and her head.
Several sportswomen have returned to competition at these Commonwealth Games following the high-profile case of tennis star Serena Williams.
Double Olympic shot put champion Valerie Adams gave birth last October and won silver on Friday, while Vanuatu beach volleyball player Miller Pata won bronze in front of her seven-month-old toddler, Tommy.
Kom, who has spoken repeatedly at the Games in Australia about the problems facing women and girls in India, said being away for long periods for competition and to train was challenging emotionally.
"Willpower, mentally strong," she said, asked how she coped with it.
"That's really required being a woman, especially leaving the family, leaving the children, they are very small."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.